Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors inside the central nervous system, conolidine modulates alternate molecular targets. A Science Improvements research found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://eddiev197vyz9.wikijm.com/user